Avidity Biosciences, Inc. has raised $400.2M in total funding.
Avidity Biosciences, Inc. is headquartered in San Diego, CA.
Rare muscle diseases like myotonic dystrophy (DM1), FSHD, and Duchenne muscular dystrophy (DMD) lack therapies that reach previously inaccessible tissue and address their underlying genetic drivers.
Avidity is developing Antibody Oligonucleotide Conjugates (AOC), a new class of RNA therapeutics aimed at the root cause of these muscle diseases.
Their AOC platform is described as combining the specificity of monoclonal antibodies with the precision of oligonucleotides to reach cell types previously inaccessible to RNA therapeutics.
Novartis completed its acquisition of Avidity Biosciences in 2026, folding the San Diego RNA-therapeutics company into its late-stage neuroscience pipeline.
Free to use in articles, research, and reference works. Stable URL, will not change. Data on this page last updated August 26, 2026.